- About Us
- Business Domains
- Muse Cells and Regenerative Medicine
- Contact Us
The mission of the Life Science Institute, Inc. (LSII) Group is to provide cutting-edge, high quality healthcare solutions to all individuals, while delivering new value to patients and their families as well as to physicians and other healthcare providers. We believe that helping everyone achieve a healthier life, starting with those who have health issues, will contribute to a better, more sustainable society.
Companies that are engaged in business directly related to human health must maintain an impeccable sense of integrity and ethics. The LSII Group Charter of Corporate Behavior sets the norms in this regard, and we believe that business can only be achieved by compliance with its tenets.
All employees of the LSII Group are knowledgeable of compliance issues and focused on pursuing innovation for the next generation of health and medical care. We will continue to fulfill our responsibility as a healthcare company by contributing to health maintenance, disease treatment, and improving quality of life in balance with our corporate growth strategies.
Satoshi MorimotoChief Sustainability Officer
Managing Executive Officer
Life Science Institute, Inc.
November 1, 2015
The LSII Group belongs to the Mitsubishi Chemical Holdings (MCHC) Group, which has established a mission to maintain the well-being of people, society, and our planet Earth — that is, realizing KAITEKI. Promoting KAITEKI to solve problems in many fields is an ideal that leads to the well-being of individuals, society, and the planet Earth now and in the future. This is encapsulated by the MCHC Group's corporate message of "KAITEKI Value for Tomorrow”
The MCHC Group identifies critical management issues among the challenges confronting us to realize KAITEKI, and we call this process "Materiality Assessment". To resolve these critical management issues (materiality), KAITEKI management is practiced on the basis of the group business activity value standards of (1) Sustainability, (2) Health, and (3) Comfort.
The LSII Group bears responsibility for the MCHC Group's healthcare segment, taking on the challenge of contributing to the pursuit of health and the treatment of diseases, both of which are healthcare-related aspects of materiality. LSII prioritizes the following three business fields: (1) Development of CL2020, a Muse cell-based product for regenerative medicine that responds to unmet medical needs*1, (2) Development of new technologies that increase the quality of treatment through Information & Communication Technology (ICT), and (3) Development of cutting-edge technologies that contribute to drug development. We are committed to contributing to the health and well-being of people around the world by developing a Next-generation Healthcare business and creating a society where everyone can live a healthy and peaceful life, KAITEKI.
*1 Unmet medical needs: Conditions for which there are currently no satisfactory diagnosis, prevention, or treatment methods available